According to a related PharmaTimes report, Sir Andrew Dillon (NICE Chief Executive) suggested that the £20,000-£30,000 per QALY cost-effectiveness threshold currently used “represents a reasonable compromise between ensuring everyone has fair and equitable access to the NHS and enabling access to new and innovative treatments”. He went on to say that “unless you believe that drug companies would be prepared to lower their prices in an unprecedented way, reducing the threshold to £13,000 per QALY would mean the NHS closing the door on most new treatments”.